Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec.

Abstract

Voretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic <i>RPE65</i> mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue. Seven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic <i>RPE65</i> mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months. All except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R²>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R²=0.5). The presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function.